Floatz logo

LENVATINIB

Differentiated Thyroid Cancer (DTC)

Eisai LimitedSmall moleculePhase 1/2Dormant
CCC
50/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
89/ 100

Competitive context

11 Active assets in the Differentiated Thyroid Cancer (DTC) cohort.

Asset / SponsorPhaseRating
Bms-907351
Exelixis
Phase 3BB
Bms-907351
Exelixis
Phase 3BB
Nivolumab
Exelixis
Phase 3BB
Atezolizumab
Exelixis
Phase 3BB
Enzalutamide
Exelixis
Phase 3B

View all 14 →

Same molecule, other indications

LENVATINIB is also rated in:

Primary Peritoneal Cavity CancerDormant
BBB
Indicative ·
73 / 100
View asset →
Stage IIB Breast CancerDormant
BBB
Indicative ·
73 / 100
View asset →
portal vein thrombosisDormant
BBB
Indicative ·
73 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →